Latanoprostene bunod

Latanoprostene bunod
Clinical data
Trade names	Vyzulta
Other names	BOL-303259-X
AHFS/Drugs.com	Monograph
License data	US DailyMed: Latanoprostene bunod;
Drug class	Prostaglandin analog
ATC code	S01EE06 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Identifiers
	IUPAC name 4-Nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate;
CAS Number	860005-21-6;
PubChem CID	11156438;
DrugBank	DB11660;
ChemSpider	9331546;
UNII	I6393O0922;
KEGG	D10441;
ChEMBL	ChEMBL2364612;
CompTox Dashboard (EPA)	DTXSID101027765 ;
ECHA InfoCard	100.251.571
Chemical and physical data
Formula	C27H41NO8
Molar mass	507.624 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@H]([C@@H]([C@H]([C@H]1O)C/C=C\CCCC(=O)OCCCCO[N+](=O)[O-])CC[C@H](CCC2=CC=CC=C2)O)O;
	InChI InChI=1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1; Key:LOVMMUBRQUFEAH-UIEAZXIASA-N;

Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.^[2]^[3] It targets the trabecular meshwork directly.^[3] It is a prostaglandin analog.^[2]

The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain).^[4] Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color.^[4]

Latanoprostene bunod was approved for medical use in the United States in November 2017.^[2]^[4]^[5]

^ "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.
^ ^a ^b ^c ^d "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
^ ^a ^b Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
^ ^a ^b ^c "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024. This article incorporates text from this source, which is in the public domain.
^ "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024 – via PR Newswire.

[1] "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.

[Vyzulta_FDA_label-2] "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.

[Hoy-3] Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.

[Vyzulta_FDA_snapshot-4] "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024. This article incorporates text from this source, which is in the public domain.

[5] "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024 – via PR Newswire.

[1]

[2]

[3]

[4]

[5]